AZD2171 in Addition to Fulvestrant in Patients With Advanced Breast Cancer.

A Phase II, Double-Blind, Placebo Controlled, Randomized Study to Assess the Efficacy and Safety of AZD2171 in Combination With Fulvestrant vs Fulvestrant Alone in Hormone Sensitive (ER+ve or PgR+ve) Post Menopausal Metastatic Breast Cancer Patients

The purpose of this study is to determine whether AZD2171 can effectively improve time to tumour progression when added to fulvestrant in patients with advanced hormone sensitive breast cancer who progressed on prior hormonal therapy.

Inclusion Criteria:

• Written informed consent
• Females with histological/cytological confirmation of hormone sensitive breast cancer with evidence of metastatic disease
• One or more evaluable lesions

Exclusion Criteria:

• Prior hormonal therapy with fulvestrant
• More than one course of prior systemic cytotoxic chemotherapy for metastatic breast cancer
• Prior biologic therapy for ABC including Anti-VEGF agents
• Radiation therapy within 4 weeks prior to provision of consent